MRI method may bump off some liver biopsies

An emerging MRI technique has shown an ability to noninvasively ferret out a relatively common, often symptomless liver condition that clinically resembles drinking-induced liver disease and that typically requires biopsy for accurate diagnosis.

Like the alcohol-associated version, nonalcoholic steatohepatitis (NASH)—an advanced form of nonalcoholic fatty liver disease (NAFLD), which occurs in more than 60 percent of obese persons and around 20 percent of the non-obese—can lead to cirrhosis or liver cancer.

Researchers at the University of California-San Diego used the imaging method, called MRI-PDFF for MRI-estimated proton-density-fat-fraction, to measure fat density in the livers of 35 patients with confirmed NASH diagnoses.

Janki Patel, MD, and colleagues compared the imaging results with paired liver histology data from the study cohort.

According to their study report, running in the September edition of Therapeutic Advances in Gastroenterology, the team found that a relative reduction of 29 percent in liver fat on MRI-PDFF is associated with a histologic response in NASH.

In a news release sent by the school, senior author Rohit Loomba, MD, says MRI-PDFF “has the potential to be a cost-effective and convenient method for liver fat quantification. It requires only a single, 20-second breath hold and an estimated time of about five minutes in an MRI scanner.”

In their study abstract, the authors conclude that their results can be incorporated into designing future NASH clinical trials, “especially those utilizing change in hepatic fat quantified by MRI-PDFF, as a treatment endpoint.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.